{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-25-000002","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.725214+00:00","generated_at":"2026-05-28T02:37:29.408027+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ANI Pharma prelim Q4/FY24 Cortrophin Gel rev $197.8-198.4M; FY25 rev guidance $739-759M","bullets":["Cortrophin Gel net rev Q4: $59.2-59.8M; FY24: $197.8-198.4M.","ILUVIEN/YUTIQ net rev Q4: $26.6-27.2M; post-acquisition period (Sep 16-Dec 31): $30.4-31.0M.","FY24 total rev, adjusted EBITDA, adjusted EPS expected at or above guidance issued Nov 8, 2024.","FY25 outlook: total rev $739-759M (24-27% growth vs FY24 midpoint); adj EBITDA $182-192M.","Full FY24 and detailed FY25 guidance to be reported in late Feb 2025 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-25-000002","json":"https://secwatch.observer/filing/0001023024-25-000002.json","markdown":"https://secwatch.observer/filing/0001023024-25-000002.md","text":"https://secwatch.observer/filing/0001023024-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000002/0001023024-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000002/ani-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:37:29.408027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}